In this study, we investigate the effect of the joint application of GANT61 and a PERK inhibitor or a PERK siRNA (reducing PERK protein expression) on MYCN-amplified NB cells and discuss the potential of this strategy in therapeutics. The gene discussed is EIF2AK3; the disease is neuroblastoma.